32:
289:
53:
284:
166:
178:
86:
49:
Pages in category "Experimental drugs developed for non-alcoholic fatty liver disease"
278:
202:
161:
132:
224:
219:
115:
36:
241:
214:
98:
66:
236:
144:
265:
127:
110:
81:
76:
71:
253:
190:
52:
The following 24 pages are in this category, out of 24 total.
149:
20:This category has only the following subcategory.
8:
54:This list may not reflect recent changes
7:
33:Fibroblast growth factor 21 analogs
58:
22:
14:
290:Non-alcoholic fatty liver disease
1:
306:
167:Lipogenesis inhibitor
285:Experimental drugs
297:
179:Obeticholic acid
38:
305:
304:
300:
299:
298:
296:
295:
294:
275:
274:
273:
272:
271:
270:
258:
246:
229:
207:
195:
183:
171:
154:
137:
120:
103:
91:
46:
45:
44:
43:
40:
39:
12:
11:
5:
303:
301:
293:
292:
287:
277:
276:
269:
268:
262:
259:
257:
256:
250:
247:
245:
244:
239:
233:
230:
228:
227:
222:
217:
211:
208:
206:
205:
199:
196:
194:
193:
187:
184:
182:
181:
175:
172:
170:
169:
164:
158:
155:
153:
152:
147:
141:
138:
136:
135:
130:
124:
121:
119:
118:
113:
107:
104:
102:
101:
95:
92:
90:
89:
87:Azemiglitazone
84:
79:
74:
69:
63:
60:
59:
50:
47:
42:
41:
31:
30:
27:
24:
23:
18:
15:
13:
10:
9:
6:
4:
3:
2:
302:
291:
288:
286:
283:
282:
280:
267:
264:
263:
260:
255:
252:
251:
248:
243:
240:
238:
235:
234:
231:
226:
223:
221:
218:
216:
213:
212:
209:
204:
201:
200:
197:
192:
189:
188:
185:
180:
177:
176:
173:
168:
165:
163:
160:
159:
156:
151:
148:
146:
143:
142:
139:
134:
131:
129:
126:
125:
122:
117:
114:
112:
109:
108:
105:
100:
97:
96:
93:
88:
85:
83:
80:
78:
75:
73:
70:
68:
65:
64:
61:
57:
55:
48:
34:
29:
28:
25:
21:
17:Subcategories
16:
203:Rencofilstat
162:Lanifibranor
133:Efruxifermin
51:
19:
225:Semaglutide
220:Selvigaltin
116:Denifanstat
279:Categories
242:Tipelukast
215:Seladelpar
99:Belapectin
67:Aldafermin
237:TERN-501
145:HEC96719
266:ZSP1601
128:EDP-305
111:DA-1241
82:AZD2693
77:AXA1125
72:ARO-HSD
254:VK2809
191:PXL065
37:(3 P)
150:HU6
281::
56:.
35:
261:Z
249:V
232:T
210:S
198:R
186:P
174:O
157:L
140:H
123:E
106:D
94:B
62:A
26:F
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.